drugset / Trial / NCT00417872

Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

NCT00417872

Phase 2 Completed 114 enrolled Romark Laboratories L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to demonstrate non-inferiority of nitazoxanide administered 500 mg b.i.d compared to metronidazole administered 250 mg q.i.d. in resolving symptoms of Clotridium difficile colitis after seven days of treatment. Secondary objectives are to provide information on the times from first dose to last unformed stool and resolution of symptoms of colitis, the sustained response rates for the different tratment groups and the effect of treatment on Clostridium difficile toxin enzyme immunoassay/culture results during hospitalization.

Timeline

Start
2004-01
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 250 mg
Subject Nitazoxanide Other / unclassified 500 mg